Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2009
Date:8/12/2009

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

    Highlights

    - Start of the preregistration clinical trial with Glybera(R)
      in Canada following two previous clinical trials
    - Presentation of additional data indicating that Glybera(R) offers
      a clinically important health benefit, accomplished by a significant
      and clinically important reduction in the incidence of acute
      pancreatitis in patients
    - Significant progress in research and development for other
      pipeline projects including hemophilia B, Duchenne muscular dystrophy
      and Parkinson's disease
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 25 million at June 30, 2009

Results comparison

AMT's key financial figures are well within the budgets for the first semester and therefore remain in line with the guidance that the company has given for 2009. The operating loss increased to EUR 9.9 million for the six months ended June 30, 2009, from EUR 9.1 million for the same period in 2008. This difference is primarily due to the increase of research & development costs to EUR 7.1 million from EUR 5.8 million in the same period of 2008. This increase is particularly related to the clinical development and regulatory work on the company's lead product, Glybera(R), as well as increased staffing for this and other programs. General and administrative costs decreased to EUR 2.9 million, from EUR 3.3 million in the first half of 2008, primarily as a result of decreased advisor's fees.

The net loss for the half of 2009 was EUR 9.4 million, as compared to a net loss of EUR 8.1 million for the first half of 2008.

At June 30, 2009, AMT's cash and cash equivalents amounted to E
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
7. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
11. Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 LayerBio, Inc., an MIT spinoff ... first round of seed financing from friends and family ... to develop a novel sustained-release product for ophthalmology. , ... and their commitment to this important work," said Dr. ... one of many areas in which innovations in drug ...
(Date:7/29/2014)... technologists have hurdled a number of significant technological ... revolutionary observing technology originally created for the James ... Principal Investigator Harvey Moseley, a scientist at NASA,s ... demonstrated that electrostatically actuated microshutter arrays that ... are as functional as the current technology,s ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... a new way of manufacturing microstructured surfaces that ... self-assembly of carbon nanotubes, could exhibit a variety ... and strength, or the ability to repel water ... that mechanical forces can be used to direct ... we can independently control the mechanical properties ...
Breaking Biology Technology:Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2
... COLUMBIA, Md., Oct. 16 Martek announced today,that ... of the former,stockholders of OmegaTech in ongoing litigation ... included in the,April 2002 merger agreement. In connection ... Martek common stock to the former stockholders of,OmegaTech, ...
... Bioponic,Phytoceuticals, Inc. (OTC: BPYT) ("Bioponic"), an ... serving the Complementary,Alternative Medicine (CAM) and nutraceutical ... Sales and Marketing of Southern California as ... including the states,of California, Washington, Nevada, Arizona, ...
... Full Range of Fertility Services and Surgeries, ... Dr. John Jain, a,fertility specialist with one ... announced today the grand opening of Santa ... health center in Santa,Monica, California. The center ...
Cached Biology Technology:Martek Announces Settlement of OmegaTech Milestone Litigation 2Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States 2Pioneer in Reproductive Medicine Opens The Country's First Comprehensive Fertility Practice 2
(Date:7/28/2014)... United States have a circulatory problem of the legs ... may even require surgery in serious cases. This disease ... turn, limb amputation. , At The University of Texas ... tested a non-surgical preventative treatment in a mouse model ... blood circulation. Their proof-of-concept study appears in the ...
(Date:7/28/2014)... Fifteen years ago, MIT professor John Essigmann and colleagues from ... HIV drug. They thought if they could induce the virus ... eventually die out a strategy that our immune system ... a drug, which caused HIV to mutate at an enhanced ... from patients in a small clinical trial reported in 2011. ...
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... have made a discovery that may explain how prion diseases, ... order to spread between various types of animals., The research ... change in the prions, makeup appears to give the disease ... strains with which it comes into contact. The team has ...
... what they eat, and whether horse meat might have ... headlines globally - calling for new policies in ... identification and authentication. As companies and manufacturers resort to ... public, it is estimated that up to 7% of ...
... March 11, 2013  Wake Forest Baptist Medical Center ... commercialization enterprise, Wake Forest Innovations, as well as ... Wake Forest Innovation Quarter After consultation ... and an analysis of park names worldwide, Piedmont ...
Cached Biology News:Discovery may explain how prion diseases spread between different types of animals 2DNA barcoding alone sufficient to detect fraudulent deer products 2DNA barcoding alone sufficient to detect fraudulent deer products 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 2Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 4Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 5
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
... Removal , , Removes ... cross-reactivity with other proteins , Simple, just ... Economical new surface technology, not based on ... with protein analysis. SurfactAway offers a simple ...
... SDS and Non-ionic Detergent Removal ... , Very selective, virtually no cross-reactivity with ... and discard pellet , Economical new ... , Detergents can often interfere with protein ...
... 3000 workstation automates a wide array of ... Proteomic Sample Preparation to Bio-Molecular and Cell ... of the Caliper Sciclone enables numerous combinations ... meet the needs of a given application, ...
Biology Products: